Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 peptide-pulsed dendritic cells
- Development stage
- Phase 2
- Lead developer
- Keio University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
WT1 peptide-pulsed dendritic cells (WT1-DC) is an autologous dendritic cell-based cancer vaccine and immunotherapy modality. The therapy consists of mature dendritic cells derived from a patient's own peripheral blood, which are subsequently pulsed with Wilms' tumor 1 (WT1) peptides. These peptides typically include both MHC class I-restricted (killer) and MHC class II-restricted (helper) peptides to elicit a comprehensive T-cell response. The vaccine is designed to stimulate the patient's immune system to recognize and eliminate cells expressing the WT1 protein, a tumor-associated antigen that is overexpressed in various malignancies. It has been primarily investigated in Japan for the treatment of advanced pancreatic cancer, esophageal cancer, and hematological malignancies, often in combination with standard chemotherapy regimens.
- Other names
- WT1-pulsed dendritic cell vaccineWT-1-pulsed dendritic cell vaccineWT 1-pulsed dendritic cell vaccineWT1-pulsed DC vaccineWT-1-pulsed DC vaccineWT 1-pulsed DC vaccineWilms' tumor 1 peptide-pulsed dendritic cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on WT1 peptide-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 peptide-pulsed dendritic cells.